15.84 USD
-0.08 (-0.5%)
15.84 USD
0 (0%)
Taking everything into account, EYPT scores 4 out of 10 in our fundamental rating. EYPT was compared to 190 industry peers in the Pharmaceuticals industry. While EYPT has a great health rating, there are worries on its profitability. EYPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year EYPT has reported negative net income.
- EYPT had a negative operating cash flow in the past year.
- EYPT had negative earnings in each of the past 5 years.
- EYPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- EYPT has a worse Return On Assets (-81.75%) than 75.79% of its industry peers.
- EYPT has a worse Return On Equity (-102.78%) than 64.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.75% | ||
| ROE | -102.78% | ||
| ROIC | N/A |
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- EYPT has a Gross Margin of 94.08%. This is amongst the best in the industry. EYPT outperforms 95.79% of its industry peers.
- EYPT's Gross Margin has been stable in the last couple of years.
- EYPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
2. Health
2.1 Basic Checks
- EYPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, EYPT has more shares outstanding
- EYPT has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- EYPT has an Altman-Z score of 7.77. This indicates that EYPT is financially healthy and has little risk of bankruptcy at the moment.
- With a decent Altman-Z score value of 7.77, EYPT is doing good in the industry, outperforming 78.42% of the companies in the same industry.
- There is no outstanding debt for EYPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.77 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
- EYPT has a Current Ratio of 7.18. This indicates that EYPT is financially healthy and has no problem in meeting its short term obligations.
- EYPT has a better Current ratio (7.18) than 71.05% of its industry peers.
- A Quick Ratio of 7.11 indicates that EYPT has no problem at all paying its short term obligations.
- EYPT's Quick ratio of 7.11 is fine compared to the rest of the industry. EYPT outperforms 71.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.18 | ||
| Quick Ratio | 7.11 |
3. Growth
3.1 Past
- The earnings per share for EYPT have decreased strongly by -49.50% in the last year.
- The Revenue has decreased by -7.38% in the past year.
- Measured over the past years, EYPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.26% on average per year.
EPS 1Y (TTM)-49.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
Revenue 1Y (TTM)-7.38%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%-90.82%
3.2 Future
- The Earnings Per Share is expected to grow by 24.78% on average over the next years. This is a very strong growth
- Based on estimates for the next years, EYPT will show a very strong growth in Revenue. The Revenue will grow by 69.99% on average per year.
EPS Next Y-33.43%
EPS Next 2Y-13.65%
EPS Next 3Y-6.12%
EPS Next 5Y24.78%
Revenue Next Year-25.48%
Revenue Next 2Y-53.7%
Revenue Next 3Y20.94%
Revenue Next 5Y69.99%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- EYPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year EYPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as EYPT's earnings are expected to decrease with -6.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.65%
EPS Next 3Y-6.12%
5. Dividend
5.1 Amount
- No dividends for EYPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15.84
-0.08 (-0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-03 2026-03-03/amc
Inst Owners84.19%
Inst Owner Change-0.01%
Ins Owners2.73%
Ins Owner Change0.35%
Market Cap1.31B
Revenue(TTM)42.34M
Net Income(TTM)-205.75M
Analysts85.56
Price Target36.81 (132.39%)
Short Float %9.4%
Short Ratio5.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.37%
Min EPS beat(2)-6.19%
Max EPS beat(2)-4.55%
EPS beat(4)1
Avg EPS beat(4)-8.28%
Min EPS beat(4)-25.16%
Max EPS beat(4)2.78%
EPS beat(8)3
Avg EPS beat(8)-4.09%
EPS beat(12)5
Avg EPS beat(12)-21.87%
EPS beat(16)8
Avg EPS beat(16)-14.5%
Revenue beat(2)0
Avg Revenue beat(2)-46.33%
Min Revenue beat(2)-71.55%
Max Revenue beat(2)-21.1%
Revenue beat(4)2
Avg Revenue beat(4)27.57%
Min Revenue beat(4)-71.55%
Max Revenue beat(4)200.52%
Revenue beat(8)5
Avg Revenue beat(8)22.34%
Revenue beat(12)7
Avg Revenue beat(12)16.22%
Revenue beat(16)9
Avg Revenue beat(16)12.42%
PT rev (1m)10.87%
PT rev (3m)2.56%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)0.8%
EPS NY rev (1m)0.36%
EPS NY rev (3m)0.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-68.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 30.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.55 | ||
| P/tB | 6.55 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.99
EYN/A
EPS(NY)-2.98
Fwd EYN/A
FCF(TTM)-2.58
FCFYN/A
OCF(TTM)-2.55
OCFYN/A
SpS0.51
BVpS2.42
TBVpS2.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.75% | ||
| ROE | -102.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.08% | ||
| FCFM | N/A |
ROA(3y)-35.96%
ROA(5y)-35.91%
ROE(3y)-57.18%
ROE(5y)-89.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.5%
GM growth 5Y1.04%
F-Score4
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 128.87% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.18 | ||
| Quick Ratio | 7.11 | ||
| Altman-Z | 7.77 |
F-Score4
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)367.17%
Cap/Depr(5y)224.18%
Cap/Sales(3y)7.38%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
EPS Next Y-33.43%
EPS Next 2Y-13.65%
EPS Next 3Y-6.12%
EPS Next 5Y24.78%
Revenue 1Y (TTM)-7.38%
Revenue growth 3Y5.42%
Revenue growth 5Y16.26%
Sales Q2Q%-90.82%
Revenue Next Year-25.48%
Revenue Next 2Y-53.7%
Revenue Next 3Y20.94%
Revenue Next 5Y69.99%
EBIT growth 1Y-86.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.63%
EBIT Next 3Y24.5%
EBIT Next 5YN/A
FCF growth 1Y-2419.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1802.28%
OCF growth 3YN/A
OCF growth 5YN/A
EYEPOINT INC / EYPT FAQ
What is the ChartMill fundamental rating of EYEPOINT INC (EYPT) stock?
ChartMill assigns a fundamental rating of 4 / 10 to EYPT.
What is the valuation status of EYEPOINT INC (EYPT) stock?
ChartMill assigns a valuation rating of 0 / 10 to EYEPOINT INC (EYPT). This can be considered as Overvalued.
What is the profitability of EYPT stock?
EYEPOINT INC (EYPT) has a profitability rating of 1 / 10.
How financially healthy is EYEPOINT INC?
The financial health rating of EYEPOINT INC (EYPT) is 8 / 10.
What is the earnings growth outlook for EYEPOINT INC?
The Earnings per Share (EPS) of EYEPOINT INC (EYPT) is expected to decline by -33.43% in the next year.